Bromodomain (BrD) Family Members as Regulators of Cancer Stemness-A Comprehensive Review

Int J Mol Sci. 2023 Jan 4;24(2):995. doi: 10.3390/ijms24020995.

Abstract

Epigenetic mechanisms involving DNA methylation and chromatin modifications have emerged as critical facilitators of cancer heterogeneity, substantially affecting cancer development and progression, modulating cell phenotypes, and enhancing or inhibiting cancer cell malignant properties. Not surprisingly, considering the importance of epigenetic regulators in normal stem cell maintenance, many chromatin-related proteins are essential to maintaining the cancer stem cell (CSC)-like state. With increased tumor-initiating capacities and self-renewal potential, CSCs promote tumor growth, provide therapy resistance, spread tumors, and facilitate tumor relapse after treatment. In this review, we characterized the epigenetic mechanisms that regulate the acquisition and maintenance of cancer stemness concerning selected epigenetic factors belonging to the Bromodomain (BrD) family of proteins. An increasing number of BrD proteins reinforce cancer stemness, supporting the maintenance of the cancer stem cell population in vitro and in vivo via the utilization of distinct mechanisms. As bromodomain possesses high druggable potential, specific BrD proteins might become novel therapeutic targets in cancers exhibiting de-differentiated tumor characteristics.

Keywords: ATAD2; BRD4; TRIM28; bromodomain; cancer stem cells; cancer stemness; epigenetic factor; pluripotency; self-renewal.

Publication types

  • Review

MeSH terms

  • Chromatin / metabolism
  • DNA Methylation
  • Epigenesis, Genetic
  • Humans
  • Neoplasms* / metabolism
  • Neoplastic Stem Cells / metabolism

Substances

  • Chromatin